May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
Antiproliferative and Cytotoxic Properties of Bevacizumab (Avastin®) on Different Cultured Ocular Cell Lines
Author Affiliations & Notes
  • A. Sierra
    Eye–hospital Tuebingen, Germany, Tuebingen, Germany
  • Tuebingen Bevacizumab Study Group
    Eye–hospital Tuebingen, Germany, Tuebingen, Germany
  • Footnotes
    Commercial Relationships  A. Sierra, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 4488. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Sierra, Tuebingen Bevacizumab Study Group; Antiproliferative and Cytotoxic Properties of Bevacizumab (Avastin®) on Different Cultured Ocular Cell Lines . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4488.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate the cytotoxic and antiproliferative properties of Bevacizumab (Avastin®) – a humanized monoclonal antibody against vascular endothelial growth factor (VEGF) – on a human retinal pigment epithelium cells line (ARPE19), a rat ganglion cell line (RGC–5), human corneal keratocytes as well as pig choroidal endothelial cells.

Methods: : For cytotoxicity assays cells were grown to confluence and then cultured in a serum–deficient medium to ensure a static milieu. MTT assay was performed after 1 day of incubation with 0.008 mg/ml, 0.025 mg/ml, 0.08 mg/ml, 0.25 mg/ml, 0.8 mg/ml, and 2.5 mg/ml, respectively, of Bevacizumab. Nonconfluent cultures of the above mentioned cells were used to carry out proliferation assays. Bevacizumab (diluted in culture medium, concentrations as above) was added and cellular proliferative activity was monitored by BrdU–incorporation into cellular DNA after 1, 3 and 6 days. Immune histochemistry was done by using the VEGF (C–1): sc–7269 mouse–monoclonal antibody.

Results: : Bevacizumab was neither cytotoxic nor antiproliferative on all cell types even at the highest concentration tested. Immune histology revealed that all cultured cell types stained positive for VEGF with ARPE–19 cells being most intensively stained.

Conclusions: : No toxic or anti–proliferative effect of bevacizumab on various ocular cell types could be observed. These results show that although the cells express VEGF, the humanised monoclonal anti–VEGF antibody has no damaging effect.

Keywords: cell survival • drug toxicity/drug effects • immunohistochemistry 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.